Teva Announces FDA Approval of ProAir RespiClick

JERUSALEM–(BUSINESS WIRE)–Apr. 1, 2015– Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albuterol sulfate) inhalation powder, a breath-actuated,…
Drugs.com – New Drug Approvals

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us